Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review.
Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review.
复制标题
帕比司他治疗复发性或/和难治性多发性骨髓瘤的疗效和安全性：临床试验和系统评价的荟萃分析
DOI：
10.1038/srep27361
复制
发表时间：
2016-06-07
影响因子：
4.6
通讯作者：
Hu Y
中科院分区：
文献类型：
--
作者：
Liu JD;Sun CY;Tang L;Wu YY;Wang QY;Hu B;Hu Y
在过去的几十年中，许多新药改善了多发性骨髓瘤患者的反应和生存。然而，当他们复发时，这仍然具有挑战性。因此，需要新的治疗剂。我们的目的是评估新型药物帕比司他对复发或/和难治性多发性骨髓瘤患者的疗效和安全性。系统性文献综述确定了有关帕比司他治疗复发性或/和难治性 MM 患者的临床试验研究。我们检索了 2000 年 1 月至 2015 年 12 月期间在 Pubmed、Ovid、EBSCO 和 Cochrane 图书馆发表的研究。计算总体缓解率和常见不良反应发生率的随机效应汇总估计值。结果显示，共有 11 项临床试验，包括 700 名接受帕比司他治疗的复发性或/和难治性 MM 患者。 ORR 在 0.08 到 0.67 之间变化。汇总分析结果显示，帕比司他与任何其他药物联合使用的 ORR 为 0.45（95% CI：0.31~0.59，I2= 90.5%，P= 0.000）。最常见的3/4级不良反应为血小板减少、中性粒细胞减少、淋巴细胞减少、贫血、腹泻、疲劳、恶心等。总之，根据我们的分析，帕比司他联合其他药物的治疗方案似乎对复发或/和难治性 MM 患者具有良好的耐受性和有效性。
During the past decades, many novel agents have improved response and survival of patients with multiple myeloma. Nevertheless, it remains challenging when they suffer relapsing. Thus, novel therapeutic agents are needed. We aimed to assess the efficacy and safety of a novel agent panobinostat for patients with relapsed or/and refractory MM. A systematic literature review identified studies for clinical trials about panobinostat in patients with relapsed or/and refractory MM. We searched studies published between January 2000 and December 2015 in Pubmed, Ovid, EBSCO and the Cochrane library. Random-effect pooled estimates were calculated for overall response rate and rates of common adverse effects. The results showed 11 clinical trials including 700 patients with relapsed or/and refractory MM treated with panobinostat were identified. The ORR varied between 0.08 and 0.67. Pooled analyses showed the results that the ORR was 0.45 (95% CI: 0.31–0.59,I2= 90.5%,P= 0.000) for panobinostat combined with any other kind of drugs. The most common Grade3/4 adverse effects were thrombocytopenia, neutropenia, lymphopenia, anemia, diarrhea, fatigue, nausea and so on. In conclusion, based on our analyses, the regimen of panobinostat combining with other agents seems to be well tolerated and efficacious in patients with relapsed or/and refractory MM.